Tuesday, February 28, 2017 8:57:52 AM
52 minutes ago - DJNF
SAN DIEGO, Feb. 28, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that its product candidate Resolaris(TM) was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of limb girdle muscular dystrophy (LGMD) patients.
"Receiving Orphan Drug Designation for the treatment of all types of LGMD patients with Resolaris is an important step in our overall process of bringing our first Physiocrine-based product candidate to the market to treat patients," said John Mendlein, CEO of aTyr Pharma. "This designation follows our recently granted Fast Track designation and our promising signals of clinical activity in a LGMD sub-type (LGMD2B). We are excited to continue the development of Resolaris to treat patients with rare myopathies with an immune component who currently have limited or no therapeutic treatment options."
The FDA's Orphan Drug Designation program is intended to advance the development of products which demonstrate promise in diagnosing or treating rare conditions that affect fewer than 200,000 people in the U.S. Sponsors developing orphan-designated products are eligible for incentives under the program, including seven years of market exclusivity following FDA approval, waiver or partial payment of application fees, and certain tax credits.
DUKE BASKETBALL and NOTRE DAME FOOTBALL
Recent LIFE News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/13/2024 08:42:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:07:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:02:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 12:30:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:26:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:21:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 12:34:42 PM
- aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR” • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 08:03:07 PM
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/24/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:27:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:19:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:11:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 11:07:42 PM
- aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference • GlobeNewswire Inc. • 05/15/2024 11:00:00 AM
- aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- aTyr Pharma to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update • GlobeNewswire Inc. • 05/02/2024 08:00:00 PM
- aTyr Pharma to Participate in April Investor Conferences • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update • GlobeNewswire Inc. • 03/14/2024 08:00:00 PM
- aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants • GlobeNewswire Inc. • 02/21/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:20:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:15:45 AM
- aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity • GlobeNewswire Inc. • 01/29/2024 01:00:00 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM